title: 3-Deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells.
abstract: BACKGROUND
  Recent studies have shown that 3-deazaneplanocin A (DZNep), a well-known histone methyltransferase inhibitor, disrupts polycomb-repressive complex 2 (PRC2), and induces apoptosis, while inhibiting proliferation and metastasis, in cancer cells, including acute myeloid leukemia, breast cancer and glioblastoma. However, little is known about effects of DZNep on ovarian cancer cells.
  
  
  METHODS
  We here therefore studied DZNep-treated A2780 ovarian cancer cells in vitro. Proliferation of ovarian cancer cells under treatment of DZNep was assessed by MTT and apoptosis by flow cytometry. Cell wound healing was applied to detect the migration. Finally, we used q-PCR to assess the migration-related gene, E-cadherin.
  
  
  RESULTS
  DZNep could inhibit the proliferation of A2780 and induce apoptosis Furthermore, it inhibited migration and increased the expression of E-cadherin (P<0.05).
  
  
  CONCLUSIONS
  DZNep is a promising therapeutic agent for ovarian cancer cells, with potential to inhibite proliferation, induce apoptosis and decrease migration.
authors.affiliation: Department of Obstetrics and Gynaecology, Provincial Hospital Affiliated to Shandong University, Shandong, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Shen
authors.forename: Jing
authors.initials: J
authors.lastname: Cui
authors.forename: Ying-Xin
authors.initials: YX
authors.lastname: Pang
authors.forename: Yan-Hui
authors.initials: YH
authors.lastname: Ma
authors.forename: Pei-Shu
authors.initials: PS
authors.lastname: Liu
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015820:Cadherins / Q000096:biosynthesis; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase / Q000037:antagonists & inhibitors; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D063151:Polycomb Repressive Complex 2 / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D015820:Cadherins; D004791:Enzyme Inhibitors; C570567:MTF2 protein, human; C048460:3-deazaneplanocin; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase; D063151:Polycomb Repressive Complex 2; D000241:Adenosine